Understanding the Complex Landscape of Oncology Drug Shortages
October 3rd 2023In an interview, Nathan Bahary, MD, PhD, explains what factors have contributed to the rise in oncology drug shortages, and emphasizes the importance of proactive measures moving forward, while also suggesting the importance of policy changes and increased communication.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Physicians Discuss Modifying Use of CDK4/6 Inhibitors in ER+/HR+ Metastatic Breast Cancer
September 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.
Read More
FDA Fast Tracks IDE161 for BRCA1/2-Mutated HR+/HER2- Breast Cancer
September 28th 2023IDE161 now has 2 fast track designations from the FDA for patients with breast cancer and ovarian cancer. The agent continues to be evaluated in a first-in-human, phase 1 study for patients with advanced solid tumors.
Read More
2 Clarke Drive
Cranbury, NJ 08512